Moving well beyond the traditional approach of testing a vaccine’s collective response in large populations, this precision approach can identify how an individual’s own immune system responds to a vaccine, offering an unprecedented opportunity to measure vaccine safety and effectiveness
The company plans to launch the product immediately
All of Us Research Program releases genomic data to researchers, combined with participant-generated data collected on Vibrent Health’s research platform
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
Successful proposals will secure fully funded postdoctoral research positions
Subscribe To Our Newsletter & Stay Updated
